Celldex Therapeutics Q2 EPS $(0.65) Beats $(0.67) Estimate, Sales $268.00K Miss $530.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics reported Q2 earnings per share (EPS) of $(0.65), beating the estimate of $(0.67) by 2.99%. However, the company's sales of $268.00K missed the estimate of $530.00K by 49.43%. Despite the miss, this represents a 64.42% increase in sales compared to the same period last year.
August 08, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Celldex Therapeutics' Q2 EPS beat estimates, but sales fell short. Despite the sales miss, there was a significant YoY increase.
Celldex Therapeutics' Q2 earnings beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is a negative factor. The impact of these two factors may offset each other in the short term, leading to a neutral score. The YoY increase in sales could be a positive signal for long-term investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100